Back to Research

Organization profile

Neurimmune

Neurimmune is a clinical-stage biopharmaceutical company that specializes in the discovery and development of human-derived antibody therapeutics for neurodegenerative and protein aggregation diseases. By utilizing its proprietary Reverse Translational Medicine platform, the company identifies protective immune memories from healthy aged donors to create high-affinity treatments for Alzheimer’s, ALS, and ATTR cardiomyopathy.

Schlieren, SwitzerlandFounded 2006

Overview

1. Executive Summary (Confidence: High)

Neurimmune is a cornerstone of the modern geroscience industry, best known for the discovery of aducanumab, the first FDA-approved treatment targeting amyloid-beta plaques in Alzheimer’s patients. The company’s unique "Reverse Translational Medicine" (RTM) technology platform bypasses traditional drug discovery hurdles by starting with natural human antibodies found in resilient populations. As of early 2024, Neurimmune has strategically regained the global rights to the entire aducanumab portfolio from Biogen, including a high-potential subcutaneous version (NI101SQ) currently in Phase 3. With a diversified pipeline targeting cardiovascular (ATTR-CM), CNS (ALS, FTD), and metabolic (Type Diabetes) disorders, Neurimmune leverages deep partnerships with AstraZeneca, Ono Pharmaceutical, and TVM Capital to bring disease-modifying therapies to market.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.